SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
|
|
Commission
File Number 000-50133
|
NOTIFICATION
OF LATE FILING
T Form
10-K
|
¨
Form 11-K
|
¨
Form 20-F
|
¨
Form 10-Q
|
¨
Form N-SAR
|
|
|
|
For
Period Ended: December 31, 2005
¨
Transition Report on Form 10-K
|
¨
Transition Report on Form 10-Q
|
¨
Transition Report on Form 20-F
|
¨
Transition Report on Form N-SAR
|
|
|
For
the
Transition Period Ended: _______________________________________
Nothing
in this form shall be construed to imply that the Commission has verified
any
information contained herein.
If
the
notification relates to a portion of the filing checked above, identify the
item(s) to which the notification
relates:_____________________________________________________________________________
PART
I
REGISTRANT
INFORMATION
Full
name of registrant
|
Grant
Life Sciences, Inc.
|
Former
name if applicable
|
|
Address
of principal executive office
|
64
East Winchester, Suite 205
|
City,
state and zip code
|
Murray,
Utah 84107
|
PART
II
RULE
12b-25 (b) AND (c)
If
the
subject report could not be filed without unreasonable effort or expense
and the
registrant seeks relief pursuant to Rule 12b-25 (b), the following should
be
completed. (Check box if appropriate.)
T
|
(a) The
reasons described in reasonable detail in Part III of this form
could not
be eliminated without unreasonable effort or expense;
(b) The
subject annual report, semi-annual report, transition report on
Form 10-K,
20-F, 11-K or Form 10-Q, or portion thereof will be filed on or
before the
15th
calendar day following the prescribed due date; or the subject
quarterly
report or transition report on Form 10-Q, or portion thereof will
be filed
on or before the fifth calendar day following the prescribed due
date;
and
(c) The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q,
N-SAR or
the transition report portion thereof could not be filed within the prescribed
time period.
The
registrant is in the process of preparing and reviewing the financial
information of the registrant. The process of compiling and disseminating
the
information required to be included in the Form 10-KSB for the relevant
fiscal
year, as well as the completion of the required review of the registrant's
financial information, could not be completed without incurring undue hardship
and expense. The registrant undertakes the responsibility to file such
annual
report no later than fifteen days after its prescribed due date.
PART
IV
OTHER
INFORMATION
(1)
Name
and telephone number of person to contact in regard to this
notification
Don
Rutherford
|
(801)
|
261-8736
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
(2)
Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940
during
the preceding 12 months or for such shorter period that the registrant
was
required to file such report(s) been filed? If the answer is no, identify
report(s).
(3)
Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the
earnings
statements to be included in the subject report or portion thereof?
If
so:
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate
of the results cannot be made.
Grant
Life Sciences, Inc.
Name
of
Registrant as Specified in Charter.
Has
caused this notification to be signed on its behalf by the undersigned
thereunto
duly authorized.
|
|
|
Date: March
31, 2006 |
By: |
/s/ Don
Rutherford |
|
Don
Rutherford
|
|
|